$BCTX

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 - BriaCell Therapeutics (NASDAQ:BCTXW), BriaCell Therapeutics (NASDAQ:BCTX)

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( NASDAQ:BCTX, BCTXW ) ) ( TSX:BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to ...

Original reporting
Benzinga · Globe Newswire
Published Nov 18, 2025, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 18, 2025, 2:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 - BriaCell Therapeutics (NASDAQ:BCTXW), BriaCell Therapeutics (NASDAQ:BCTX) — source image
Decision brief

The 30-second read

$BCTXBullishMed
01

Why it matters

The presentation could serve as a catalyst for stock movement, contingent on data outcomes.

02

Market read

High relevance for biotech investors and analysts tracking cancer immunotherapy developments.

03

What to watch

Market-wide biotech downturns or macroeconomic factors could overshadow company-specific news.

Timing: Immediate, as the event is scheduled for 2025-11-18

Background

BriaCell is advancing immunotherapy treatments for cancer, with upcoming data presentations at SABCS 2025.

Company-level read

Ticker impact

$BCTXBullishHigh confidence
Context

The news pertains to BriaCell Therapeutics' upcoming presentation of clinical data at SABCS 2025, which could influence investor sentiment and stock performance.

Expected impact

Moderate increase in stock price within the next 1-2 weeks.

Evidence & confidence

The presentation of Phase 2 & 3 clinical data at a reputable conference is a significant milestone that can enhance credibility and attract investor interest.

Market effects

Potential positive impact on biotech sector sentiment

Limited regional impact, primarily affecting North American biotech stocks

Moderate, as biotech conferences attract international attention

Counterpoint

The clinical data may not meet market expectations, leading to a sell-off despite the event's significance.

Key entities

  • BriaCell Therapeutics

    A clinical-stage biotechnology firm developing immunotherapies for cancer.

Related articles

$BCTXMedAI 9/10

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.

$BCTXHighAI 9/10

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (Nasdaq: BCTX; TSX: BCT) said its independent Data Safety Monitoring Board reviewed safety data from its pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer and raised no safety concerns, recommending continuation without modifications. The DSMB issued its sixth consecutive positive recommendation; the study is under FDA Fast Track.

$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

$EXCMed

Why Exelon's CFO is stepping into a new strategy role

Exelon's CFO Jeanne Jones transitions to a new role as EVP of finance and strategy on Oct. 5, focusing on long-term strategy and capital allocation. Robert Kleczynski will succeed Jones as CFO. Exelon reported Q2 revenue of $5.97 billion, up 10% YoY, beating estimates. The company is investing in infrastructure amid rising electricity demand and pressure to keep customer bills affordable.